BeiGene (NASDAQ:BGNE) Sets New 1-Year Low at $131.50

BeiGene, Ltd. (NASDAQ:BGNE) reached a new 52-week low during trading on Wednesday . The company traded as low as $131.50 and last traded at $131.83, with a volume of 48835 shares. The stock had previously closed at $134.05.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on BGNE shares. Bank of America lowered their target price on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research note on Monday, April 8th. Guggenheim lowered their target price on BeiGene from $350.00 to $345.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Sanford C. Bernstein decreased their price objective on BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. lifted their price objective on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a report on Tuesday, March 19th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, BeiGene currently has a consensus rating of “Moderate Buy” and an average target price of $251.70.

BeiGene Stock Up 0.1 %

The company has a debt-to-equity ratio of 0.06, a current ratio of 2.32 and a quick ratio of 2.09. The company has a 50-day simple moving average of $155.43 and a two-hundred day simple moving average of $168.61.

BeiGene (NASDAQ:BGNE) last announced its earnings results on Monday, February 26th. The company reported ($3.53) EPS for the quarter, beating analysts’ consensus estimates of ($3.61) by $0.08. The company had revenue of $634.40 million during the quarter, compared to the consensus estimate of $632.52 million. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($4.29) earnings per share. On average, equities analysts predict that BeiGene, Ltd. will post -8.87 EPS for the current year.

Insider Activity at BeiGene

In related news, CEO John Oyler sold 26,716 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the transaction, the chief executive officer now owns 12,084 shares in the company, valued at $1,799,186.76. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Julia Aijun Wang sold 397 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Oyler sold 26,716 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total value of $3,977,745.24. Following the completion of the sale, the chief executive officer now directly owns 12,084 shares in the company, valued at $1,799,186.76. The disclosure for this sale can be found here. Insiders sold a total of 64,781 shares of company stock worth $10,222,381 over the last quarter. 7.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BeiGene

Institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. grew its stake in shares of BeiGene by 26.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 244 shares of the company’s stock worth $54,000 after acquiring an additional 51 shares during the last quarter. Toronto Dominion Bank grew its stake in shares of BeiGene by 166.4% in the third quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after acquiring an additional 208 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its stake in shares of BeiGene by 20.5% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock worth $80,000 after acquiring an additional 76 shares during the last quarter. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of BeiGene in the fourth quarter worth $98,000. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of BeiGene by 73.5% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 694 shares of the company’s stock worth $125,000 after acquiring an additional 294 shares during the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.